Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antifibrotic therapy on regression of myocardial fibrosis after TAVI
2024-510869-42-00Phase 2Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of spironolactone in aortic stenosis (AS) and cardiac fibrosis, sponsored by Universitätsmedizin Göttingen. Primary endpoint: Reduction of ECV-derived matrix volume at 12 months. Started Jul 2024; status: completed.
02
Drugs
spironolactone
03
Conditions
aortic stenosis (AS)cardiac fibrosis
Beyond the preview
Go deeper on 2024-510869-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510869-42-00.